Y. J. Hei

TL;DR: Baseline and recent bone marker levels were predictive of negative clinical outcomes in patients with bone metastases secondary to prostate cancer and to NSCLC and other solid tumors, reflecting the key role of osteolysis in the development of skeletal complications.

TL;DR: Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history and baseline PSA and PSA velocity independently predict time to first bone metastasis and survival.

TL;DR: This exploratory analysis demonstrates that patients with a history of SREs are at high risk for subsequent S REs, but zoledronic acid reduces skeletal morbidity regardless of S RE history.

TL;DR: This exploratory analysis demonstrates that patients with a history of SREs are at high risk of subsequent S REs, and zoledronic acid reduces skeletal morbidity regardless of a prior history ofSREs.

TL;DR: This exploratory analysis suggests that patients with a history of SREs are at significantly higher risk of subsequent skeletal complications, and Zol was significantly more effective than Pam at reducing S REs in this subgroup.